LIVE POLIO IRUS VACCINES

DISCUSSION
CHAIRMAN HILLEBOE: Before we begin the discussion
of the five papers presented, Dr. Payne
has asked for the privilege of giving a brief report
from Switzerland.
DR. PAYNE: I have a report from Dr. F. Buser
and Dr. M. Schar of Bern, in cooperation with
Dr. R. Martin Du Pan and Dr. M. Paccaud of
Geneva, and Dr. P. Miiller and Dr. R. Knoepfli
of Basle, entitled "Vaccination of Children,
Infants, and Newborns against Poliomyelitis with
Live Avirulent Poliovirus."
The summary of their communication is as
follows:
Four hundred individuals, including 145 triplenegative
infants, children, and 100 newborns,
have been vaccinated against poliomyelitis with
the attenuated poliovirus Type 1, the CHAT
strain; 90 of these individuals were also vaccinated
with the Type 3 Fox strain.
Infection was established in 99 per cent for
Type 1 and 95 per cent for Type 3 of all individuals
without homologous antibody, whether or
not they had been vaccinated with the Salk vaccine
previously, as well as of all passively immune
infants over two months of age. Naturally immune
children and adults became less frequently
infected, 66 per cent and 30 per cent, respectively.
Antibody titers over 1:200 were reached in
almost 80 per cent of vaccinated persons, and
only 2 per cent of the Type 1 and 5 per cent of
the Type 3 vaccinees remained without antibody.
These high antibody levels remained practically
unchanged during an observation period
of two years.
After Type 3 vaccination, the heterologous
response to Type 2 antibody, which did not persist,
was observed in more than 50 per cent of the
vaccinated individuals. The vaccine virus was
transmitted from a vaccinated child to non-
DURATION OF VIRUS EXCRETION
100
90
80
70
60
50
40
30
96 %
61%
58 '/ ......
156 INFANTS AND CHILDREN
VACCINATED WITH TYPE I
80 INFANTS AND CHILDREN
VACCINATED WITH TYPE III
20
10
11%
Days 10
30 60
0, 6 %
90
o %
120